<p>Pancreatic cancer is the fourth leading cause of cancer death in the United States. This is in large part due to the rapidly fatal course of this disease, as the vast majority of patients die within months of diagnosis and the five-year survival rate is less than 5. We have brought together over 8000 participants from 9 studies of pancreatic cancer, to conduct a GWAS of pancreatic cancer. The studies were drawn from the Pancreatic Cancer Case-Control consortium and include case-control studies from the United States, Europe and Australia. Sites include: <a href="https://nfptr.org/">Johns Hopkins National Familial Pancreas Tumor Registry</a>, <a href="https://www.mayo.edu/research/centers-programs/pancreatic-cancer-early-detection-research-program/research">Mayo Clinic Biospecimen Resource for Pancreas Research</a>, <a href="https://www.zanecohencentre.com/gi-cancers/opcs">Ontario Pancreas Cancer Study</a> (OPCS), <a href="https://www.yale.edu/">Yale University</a>, MD Anderson Case Control Study, Queensland Pancreatic Cancer Study, <a href="https://cancer.ucsf.edu/research/pancreas">University of California San Francisco Molecular Epidemiology of Pancreatic Cancer Study</a>, <a href="https://www.iarc.who.int/">International Agency of Cancer Research</a> and <a href="https://www.mskcc.org/">Memorial Sloan Kettering Cancer Center</a>.</p>

Pancreatic Cancer Case Control Association Study

Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer

Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer

Nucleotide Excision Repair Pathway Polymorphisms and Pancreatic Cancer Risk: Evidence for role of MMS19L

Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment.